反应条件
1: caesium carbonate; tris-(dibenzylideneacetone)dipalladium(0); 9,9-dimethyl-4,5-bis(diphenyl-phosphino)xanthene / toluene; 1,4-dioxane / 8 h / 99 °C / |Inert atmosphere
2: anhydrous potassium trimethylsilanolate / N,N-dimethyl-formamide; tetrahydrofuran / 1.67 h / 20 - 25 °C / |Inert atmosphere
3: 1,1'-carbonyldiimidazole / tetrahydrofuran / 2 h / 20 - 50 °C
4: N,N-dimethyl-formamide; tetrahydrofuran / 1 h / 50 °C / |Inert atmosphere
5: phosphoric acid; water / acetonitrile / 6.25 h / 20 - 53 °C
View Scheme
参考文献
NOVARTIS AG; ARRAY BIOPHARMA INC.; KRELL, Christoph, Max; MISUN, Marian; NIEDERER, Daniel, Andreas; PACHINGER, Werner, Heinz; WOLF, Marie-christine; ZIMMERMANN, Daniel; LIU, Weidong; STENGEL, Peter, J.; NICHOLS, Paul
Patent: WO2014/63024 A1, 2014 ;